By Iain Gilbert
Date: Tuesday 07 Oct 2025
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that Baxdrostat had met its primary endpoint in the Bax24 Phase III trial, delivering a "statistically significant and clinically meaningful reduction" in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension.
Baxdrostat met primary endpoint in Bax24 Ph3 trial | 07-Oct-2025 | 07:00 | RNS |
Datroway improved OS and PFS in TROPION-Breast02 | 06-Oct-2025 | 07:30 | RNS |
Total Voting Rights | 01-Oct-2025 | 15:00 | RNS |
Enhertu improved IDFS in early BC in DB-05 | 29-Sep-2025 | 07:30 | RNS |
AZN harmonises listing structure | 29-Sep-2025 | 07:00 | RNS |
Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
Currency | UK Pounds |
Share Price | 12,780.00p |
Change Today | 54.00p |
% Change | 0.42 % |
52 Week High | 12,832.00 |
52 Week Low | 9,667.00 |
Volume | 1,593,444 |
Shares Issued | 1,550.70m |
Market Cap | £198,180m |
RiskGrade | 123 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Latest | Previous | |
---|---|---|
1st Interim | 2nd Interim | |
Ex-Div | 07-Aug-25 | 20-Feb-25 |
Paid | 08-Sep-25 | 24-Mar-25 |
Amount | 103.00¢ | 210.00¢ |
Time | Volume / Share Price |
14:32 | 0 @ 12,736.00p |
14:31 | 0 @ 12,732.00p |
14:20 | 0 @ 12,736.00p |
14:27 | 0 @ 12,744.00p |
14:26 | 0 @ 12,738.00p |
You are here: research